Local Institution

Glasgow G51 4TF

0 studies enrolling now · 8 studies all time

What they study most

Atrial Fibrillation, Atrial Flutter, Cardiac Failure, Diabetes Mellitus II, Heart Failure, Hodgkin Disease, Leukemia, Melanoma, Myeloid Leukemia, Chronic, Chronic-Phase, Reduced Ventricular Ejection Fraction

Studies at this site

• A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment — Completed
• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants — Withdrawn before enrolling
• Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure — Completed
• A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function — Completed
• Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
• Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML — Completed
• Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) — Completed
• Dose Ranging Study With LT, Monotherapy, PPAR — Completed